Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Leukemia

Leukemia

552

Pipeline Programs↗

1.2K

Active Trials↗

303

Companies Involved↗

Leukemia is a highly competitive landscape with 552 programs across 303 companies. The most active players are Essen Biotech, Guangzhou Ruixin Biotechnological Co., LTD. 80 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

100/100

Mech. Concentration

5/100

Completion Rate

70/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Essen Biotech

1 program

Guangzhou Ruixin Biotechnological Co., LTD

1 program

Pipeline

Programs by Phase

Preclinical128

Furosemide

Validus Pharmaceuticals

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Interferon Alpha

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

CD7 CAR T-Cells

iCell Gene Therapeutics

Phase 1164

Tocilizumab

Roche

AZD6738

AstraZeneca

JY231

Shenzhen Genocury Biotech Co., Ltd.

Zeprumetostat

Sun Yat-sen University

Gene-Modified T Cells Targeted

Memorial Sloan Kettering Cancer Center

Phase 2180

Tisagenlecleucel

Novartis

Intravenous Immunoglobulin

University of Alabama at Birmingham

Mononuclear Cells

National University of Malaysia

Tafasitamab

Incyte

Mosunetuzumab

Roche

Phase 380

Doxorubicin Hydrochloride

Pfizer

Mesna

Baxter Healthcare Corporation

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Tacrolimus

Veloxis Pharmaceuticals

G-CSF

Arog Pharmaceuticals, Inc.

Approved

No programs

Analysis

Modality Breakdown

70%

Small molecule

325 of 461 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 461 classified programs, each share of the total. Modality classified for 93% of 552 pipeline programs.

Analysis

Trial Status

3,979

clinical trials

Completed1,715 · 43%

Recruiting632 · 16%

Terminated534 · 13%

Active, not recruiting356 · 9%

Unknown status345 · 9%

Withdrawn170 · 4%

Other227 · 6%

Clinical Trials

Trial Activity

3979 trials

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT03150693·303 enrolled

The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial

Recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·Preclinical·NCT07912684·75 enrolled

Pilot Study of Asciminib as a Maintenance Treatment Post Cellular Therapies in Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recruiting·CCity of Hope Medical Center·Phase 1·NCT07040982·30 enrolled

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)

Recruiting·KKeystone Nano, Inc·Phase 1·NCT04716452·15 enrolled

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06484062·54 enrolled

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting·Alliance for Clinical Trials in Oncology·Phase 3·NCT07321652·466 enrolled

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06235801·40 enrolled

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Recruiting·NNurix Therapeutics, Inc.·Phase 2·NCT07221500·100 enrolled

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study

Recruiting·IInstituto do Cancer do Estado de São Paulo·N/A·NCT05959720·180 enrolled

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06967610·40 enrolled

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Recruiting·UUniversity of Ulm·Phase 3·NCT04628026·650 enrolled

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564390·2,000 enrolled

Phase 1 First-in-Human Multi-Region Clinical Trial of ORM-1153 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Other Hematological Malignancies With CD123 Expression

Recruiting·OOrum Therapeutics USA, Inc.·Phase 1·NCT07809906·42 enrolled

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06229912·40 enrolled

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Recruiting·National Cancer Institute (NCI)·Phase 3·NCT04269902·247 enrolled

Page 1 of 266

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)